JP2009533351A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009533351A5 JP2009533351A5 JP2009504359A JP2009504359A JP2009533351A5 JP 2009533351 A5 JP2009533351 A5 JP 2009533351A5 JP 2009504359 A JP2009504359 A JP 2009504359A JP 2009504359 A JP2009504359 A JP 2009504359A JP 2009533351 A5 JP2009533351 A5 JP 2009533351A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- independently
- conr
- compound
- aliphatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001931 aliphatic group Chemical group 0.000 claims description 29
- 125000005843 halogen group Chemical group 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 18
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 16
- 125000001072 heteroaryl group Chemical group 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 125000004429 atom Chemical group 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 41
- -1 2- (tertbutyl) indol-5-yl Chemical group 0.000 claims 21
- 125000004093 cyano group Chemical group *C#N 0.000 claims 18
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 claims 12
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 claims 12
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-M cyclopropanecarboxylate Chemical compound [O-]C(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- PSMIMDJBBPABLI-UHFFFAOYSA-N methyl 1-[4-hydroxy-3-(N-hydroxy-C-methylcarbonimidoyl)phenyl]cyclopropane-1-carboxylate Chemical compound C=1C=C(O)C(C(C)=NO)=CC=1C1(C(=O)OC)CC1 PSMIMDJBBPABLI-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79045906P | 2006-04-07 | 2006-04-07 | |
| US60/790,459 | 2006-04-07 | ||
| PCT/US2007/008975 WO2007117715A2 (en) | 2006-04-07 | 2007-04-09 | Modulators of atp-binding cassette transporters |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013240205A Division JP5827297B2 (ja) | 2006-04-07 | 2013-11-20 | Ａｔｐ結合カセット輸送体の調節剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009533351A JP2009533351A (ja) | 2009-09-17 |
| JP2009533351A5 true JP2009533351A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2010-06-03 |
| JP5420395B2 JP5420395B2 (ja) | 2014-02-19 |
Family
ID=38477342
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009504359A Active JP5420395B2 (ja) | 2006-04-07 | 2007-04-09 | Ａｔｐ結合カセット輸送体の調節剤 |
| JP2013240205A Active JP5827297B2 (ja) | 2006-04-07 | 2013-11-20 | Ａｔｐ結合カセット輸送体の調節剤 |
| JP2015073706A Pending JP2015120762A (ja) | 2006-04-07 | 2015-03-31 | Ａｔｐ結合カセット輸送体の調節剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013240205A Active JP5827297B2 (ja) | 2006-04-07 | 2013-11-20 | Ａｔｐ結合カセット輸送体の調節剤 |
| JP2015073706A Pending JP2015120762A (ja) | 2006-04-07 | 2015-03-31 | Ａｔｐ結合カセット輸送体の調節剤 |
Country Status (22)
Families Citing this family (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| CA2537841A1 (en) | 2003-09-06 | 2005-03-24 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| NZ547220A (en) * | 2003-11-14 | 2009-12-24 | Vertex Pharma | Thiazoles and oxazoles useful as modulators of ATP-binding cassette transporters |
| ES2631362T3 (es) * | 2004-01-30 | 2017-08-30 | Vertex Pharmaceuticals Incorporated | Moduladores de transportadores de casete de unión a ATP |
| US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| WO2007056341A1 (en) * | 2005-11-08 | 2007-05-18 | Vertex Pharmaceuticals Incorporated | Heterocyclic modulators of atp-binding cassette transporters |
| EP2532650A3 (en) | 2004-06-24 | 2013-11-06 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| MX2008002019A (es) | 2005-08-11 | 2008-04-16 | Vertex Pharma | Moduladores del regulador de conductancia transmembrana de fibrosis quistica. |
| EP3219705B1 (en) | 2005-12-28 | 2020-03-11 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| EP2016065B1 (en) | 2005-12-28 | 2012-09-19 | Vertex Pharmaceuticals Incorporated | 1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis |
| USRE50453E1 (en) | 2006-04-07 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US7645789B2 (en) * | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| ES2659364T3 (es) | 2006-04-07 | 2018-03-15 | Vertex Pharmaceuticals Incorporated | Moduladores de transportadores del casete de unión a ATP |
| NZ576642A (en) * | 2006-11-03 | 2011-11-25 | Vertex Pharma | Azaindole derivatives as cftr modulators |
| US8563573B2 (en) * | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US7754739B2 (en) * | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| EP2142498A2 (en) * | 2007-04-02 | 2010-01-13 | Institute for Oneworld Health | Cftr inhibitor compounds and uses thereof |
| NZ581259A (en) | 2007-05-09 | 2012-07-27 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| US8193194B2 (en) * | 2007-05-25 | 2012-06-05 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| JP5389030B2 (ja) | 2007-08-24 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | （特に）嚢胞性線維症の処置に有用なイソチアゾロピリジノン |
| SI2578571T1 (sl) | 2007-11-16 | 2016-01-29 | Vertex Pharmaceuticals Incorporated | Izokinolinski modulatorji prenašalcev z atp-vezavno kaseto |
| WO2009073757A1 (en) | 2007-12-07 | 2009-06-11 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
| US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| PT2639223T (pt) * | 2007-12-07 | 2017-05-08 | Vertex Pharma | Processos para produção de ácidos cicloalquilcarboxamido-piridinabenzoicos |
| CA2708146A1 (en) * | 2007-12-07 | 2009-06-18 | Vertex Pharmaceuticals Incorporated | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| EP2078711A1 (en) | 2007-12-28 | 2009-07-15 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. | (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor |
| CN102245573B (zh) * | 2008-02-28 | 2013-11-20 | 沃泰克斯药物股份有限公司 | 作为cftr调节剂的杂芳基衍生物 |
| EP2615085B1 (en) | 2008-03-31 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Pyridyl derivatives as CFTR modulators |
| WO2009131947A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyridazine derivatives |
| WO2009131957A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising oxadiazole derivatives |
| US20090264433A1 (en) * | 2008-04-21 | 2009-10-22 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Triazine Derivatives |
| WO2009131951A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
| AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
| US20110237528A1 (en) * | 2008-09-19 | 2011-09-29 | Institute For Oneworld Health | Compositions and methods comprising imidazole and triazole derivatives |
| CN102164587A (zh) | 2008-09-29 | 2011-08-24 | 沃泰克斯药物股份有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的剂量单元 |
| WO2010048526A2 (en) * | 2008-10-23 | 2010-04-29 | Vertex Pharmaceuticals, Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP2940016A1 (en) * | 2008-11-06 | 2015-11-04 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| UA104876C2 (uk) * | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятори atф-зв'язувальних касетних транспортерів |
| NO2821400T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2009-03-20 | 2018-02-24 | ||
| US8511216B2 (en) * | 2009-03-30 | 2013-08-20 | Kanzaki Kokyukoki Mfg. Co., Ltd. | Hydraulic actuator unit |
| US8343976B2 (en) * | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
| US8497271B2 (en) | 2009-10-07 | 2013-07-30 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| US8426414B2 (en) | 2009-10-09 | 2013-04-23 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| US8304577B2 (en) | 2009-10-09 | 2012-11-06 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| WO2011050325A1 (en) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
| EP2826776B1 (en) * | 2010-03-25 | 2020-11-25 | Vertex Pharmaceuticals Incorporated | Solid dispersion of amorphous form of (r)-1(2,2-difluorobenzo(d)(1,3)dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)-cyclopropanecarboxamide |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| ES2579965T3 (es) | 2010-04-07 | 2016-08-17 | Vertex Pharmaceuticals Incorporated | Las formas sólidas de 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) Ciclopropano carboxamida)-3-metilpiridin-2-il)benzoico |
| CN102917692A (zh) | 2010-04-07 | 2013-02-06 | 弗特克斯药品有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的药物组合物和其给药方法 |
| WO2011133951A1 (en) * | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| SG184987A1 (en) * | 2010-04-22 | 2012-11-29 | Vertex Pharma | Process of producing cycloalkylcarboxamido-indole compounds |
| CA2796602A1 (en) * | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| WO2011133956A1 (en) * | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| WO2011146901A1 (en) | 2010-05-20 | 2011-11-24 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
| JP2013536231A (ja) * | 2010-08-23 | 2013-09-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | （ｒ）−１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）−ｎ−（１−（２，３−ジヒドロキシプロピル）−６−フルオロ−２−（１−ヒドロキシ−２−メチルプロパン−２−イル）−１ｈ−インドール−５−イル）シクロプロパンカルボキサミドを含む医薬組成物およびその投与 |
| CN102133402B (zh) * | 2011-03-24 | 2013-06-12 | 首都医科大学附属北京同仁医院 | 囊性纤维化跨膜转导调节因子抑制剂在制备治疗糖尿病药物中的应用 |
| AU2012332225A1 (en) | 2011-11-02 | 2014-05-15 | Vertex Pharmaceuticals Incorporated | Use of (N- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - ca rboxamide) for treating CFTR mediated diseases |
| RU2640420C2 (ru) * | 2011-11-08 | 2018-01-09 | Вертекс Фармасьютикалз Инкорпорейтед | Модуляторы транспортеров атф-связывающей кассеты |
| US20130224293A1 (en) | 2012-02-27 | 2013-08-29 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US8703953B2 (en) | 2012-03-09 | 2014-04-22 | Bristol-Myers Squibb Company | Aryl ether-base kinase inhibitors |
| US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| MX361457B (es) | 2012-05-11 | 2018-12-06 | Reset Therapeutics Inc | Sulfonamidas que contienen carbazol como moduladoras de criptocromo. |
| EP2858645A1 (en) | 2012-06-08 | 2015-04-15 | Vertex Pharmaceuticals Incorporated | Pharmaceuticl compositions for the treatment of cftr -mediated disorders |
| AR092857A1 (es) | 2012-07-16 | 2015-05-06 | Vertex Pharma | Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas |
| US8901305B2 (en) | 2012-07-31 | 2014-12-02 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
| CN102816104B (zh) * | 2012-08-30 | 2014-05-21 | 浙江大学 | 一种3-氰基吲哚类化合物的合成方法 |
| ITMI20122065A1 (it) | 2012-12-03 | 2014-06-04 | Univ Padova | Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato |
| CN105121445A (zh) | 2013-02-22 | 2015-12-02 | 百时美施贵宝公司 | 作为连接蛋白相关激酶1(AAK1)抑制剂的5H-色烯并[3,4-c]吡啶 |
| EP3019475A1 (en) | 2013-07-08 | 2016-05-18 | Bristol-Myers Squibb Company | Aryl amide kinase inhibitors |
| AU2014349010C1 (en) | 2013-11-12 | 2020-08-06 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases |
| TWI690521B (zh) | 2014-04-07 | 2020-04-11 | 美商同步製藥公司 | 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類 |
| CN103922934B (zh) * | 2014-04-11 | 2016-03-30 | 北京乐威泰克医药技术有限公司 | 活泼亚甲基化合物的烷基化方法 |
| UA124567C2 (uk) | 2014-04-15 | 2021-10-13 | Вертекс Фармасьютикалз Інкорпорейтед | Фармацевтичні композиції для лікування захворювань, опосередкованих муковісцидозним регулятором трансмембранної провідності |
| NZ768373A (en) | 2014-10-06 | 2024-03-22 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| RU2749213C2 (ru) | 2014-10-07 | 2021-06-07 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе |
| KR102462038B1 (ko) * | 2014-10-31 | 2022-11-02 | 애브비 에스.에이.알.엘. | 치환된 크로만 및 이의 사용 방법 |
| PT3221692T (pt) | 2014-11-18 | 2021-09-10 | Vertex Pharma | Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência |
| HK1249893A1 (zh) | 2015-03-31 | 2018-11-16 | Vertex Pharmaceuticals (Europe) Limited | 氘代vx-661 |
| US10174044B2 (en) | 2015-04-10 | 2019-01-08 | Bristol-Myers Squibb Company | Fused pyridines as kinase inhibitors |
| CN105153105B (zh) * | 2015-08-15 | 2018-01-19 | 浙江永宁药业股份有限公司 | 1‑(2,2‑二氟苯并[d][1,3]二氧杂环戊烯‑5‑基)环丙烷甲酸的合成方法及其中间体 |
| HUE056716T2 (hu) | 2016-09-30 | 2022-03-28 | Vertex Pharma | Cisztás firbrózis transzmembrán konduktancia regulátor modulátora, gyógyszerészeti készítmények, kezelési eljárások, és eljárások a modulátor elõállítására |
| LT3551622T (lt) | 2016-12-09 | 2021-02-25 | Vertex Pharmaceuticals Incorporated | Cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatorius, farmacinė kompozicija, gydymo būdai, ir moduliatoriaus gamybos būdas |
| WO2018227049A1 (en) | 2017-06-08 | 2018-12-13 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| WO2019018395A1 (en) | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | METHODS OF TREATING CYSTIC FIBROSIS |
| TWI799435B (zh) | 2017-08-02 | 2023-04-21 | 美商維泰克斯製藥公司 | 製備化合物之製程 |
| EP3697774B1 (en) | 2017-10-19 | 2025-09-24 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
| US11498904B2 (en) | 2017-11-14 | 2022-11-15 | Merck Sharp & Dohme Llc | Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
| AR113878A1 (es) | 2017-11-14 | 2020-06-24 | Merck Sharp & Dohme | Compuestos de biarilo sustituido como inhibidores de indolamina 2,3-dioxigenasa (ido) |
| CN111757874B (zh) | 2017-12-08 | 2024-03-08 | 弗特克斯药品有限公司 | 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法 |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| JP7214743B2 (ja) | 2018-02-15 | 2023-01-30 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとしての大環状分子、それらの医薬組成物、嚢胞性線維症の治療におけるそれらの使用、及びそれらの製造方法 |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| RS65335B1 (sr) | 2018-10-05 | 2024-04-30 | Annapurna Bio Inc | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj |
| CN109880090A (zh) * | 2019-02-18 | 2019-06-14 | 华研(佛山)纳米材料有限公司 | 一种含石墨烯以及碳纳米管的聚酰亚胺导热材料、导热膜及其制备方法 |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| MX2022001828A (es) | 2019-08-14 | 2022-06-08 | Vertex Pharma | Formas cristalinas de moduladores del regulador de conductancia transmembrana de la fibrosis quistica (cftr). |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| BR112022002604A2 (pt) | 2019-08-14 | 2022-05-03 | Vertex Pharma | Processo de produção de moduladores de cftr |
| CN113748716B (zh) * | 2020-03-31 | 2022-10-28 | 华为技术有限公司 | 小区搜索的方法、装置及系统 |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| CA3188234A1 (en) | 2020-08-20 | 2022-02-24 | Jeffrey Axelrod | Methods for treating respiratory diseases characterized by mucus hypersecretion |
| CN112851493B (zh) * | 2020-11-10 | 2022-09-06 | 台州臻挚生物科技有限公司 | 一种2,4,5-三氟苯乙酸的制备方法 |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| MX2023006770A (es) | 2020-12-10 | 2023-08-14 | Vertex Pharma | Metodos de tratamiento para fibrosis quistica. |
| DE102021207925A1 (de) * | 2021-07-23 | 2023-01-26 | Continental Reifen Deutschland Gmbh | Verbindung, Verfahren zu deren Herstellung sowie Verwendung der Verbindung als Alterungsschutzmittel und/oder Ozonschutzmittel und/oder Farbstoff |
| TW202421102A (zh) | 2022-09-15 | 2024-06-01 | 瑞士商愛杜西亞製藥有限公司 | 巨環cftr調節劑與cftr校正子及/或cftr增效劑之組合 |
| WO2024056798A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
| CN115872895A (zh) * | 2023-02-22 | 2023-03-31 | 北京诺禾致源科技股份有限公司 | 用于衍生短链脂肪酸标准品作为内标的重标试剂及其制备方法、应用 |
| WO2025186214A1 (en) | 2024-03-05 | 2025-09-12 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
| CN119219506A (zh) * | 2024-10-12 | 2024-12-31 | 浙江博澳新材料股份有限公司 | 一种2-氯-4-硝基-6-溴-苯胺的合成方法 |
Family Cites Families (174)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5328173A (en) | 1976-08-06 | 1978-03-16 | Zenyaku Kogyo Kk | Novel phenylmethanenitro compound and its preparation |
| US4138397A (en) | 1978-02-27 | 1979-02-06 | Richardson-Merrell Inc. | 6-(2,3-Dihydro-5-benzofuranyl)acetamido penicillin derivatives |
| GB8524157D0 (en) * | 1984-10-19 | 1985-11-06 | Ici America Inc | Heterocyclic amides |
| JPS61103861A (ja) | 1984-10-27 | 1986-05-22 | Nitto Kasei Kk | アリ−ル置換シアン酢酸エステルの製造方法 |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| GB9005014D0 (en) * | 1990-03-06 | 1990-05-02 | Janssen Pharmaceutica Nv | N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| GB9317764D0 (en) | 1993-08-26 | 1993-10-13 | Pfizer Ltd | Therapeutic compound |
| US5510379A (en) | 1994-12-19 | 1996-04-23 | Warner-Lambert Company | Sulfonate ACAT inhibitors |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| WO1998047868A1 (en) | 1997-04-18 | 1998-10-29 | Smithkline Beecham Plc | Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists |
| AU746853B2 (en) | 1997-06-21 | 2002-05-02 | Roche Diagnostics Gmbh | Barbituric acid derivatives with antimetastatic and antitumor activity |
| DK0901786T3 (da) | 1997-08-11 | 2007-10-08 | Pfizer Prod Inc | Faste farmaceutiske dispersioner med foröget biotilgængelighed |
| US20020017295A1 (en) | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
| US6426331B1 (en) | 1998-07-08 | 2002-07-30 | Tularik Inc. | Inhibitors of STAT function |
| ES2359235T3 (es) | 1999-02-24 | 2011-05-19 | F. Hoffmann-La Roche Ag | Derivados de 4-fenilpiridina y su empleo como antagonistas del receptor nk-1. |
| ATE329920T1 (de) | 1999-09-10 | 2006-07-15 | Novo Nordisk As | Modulatoren der protein tyrosin phosphatase (ptpases) |
| IT1315267B1 (it) | 1999-12-23 | 2003-02-03 | Novuspharma Spa | Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale |
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| EP1262475A4 (en) * | 2000-03-09 | 2005-01-05 | Ono Pharmaceutical Co | INDOIND DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE |
| DE10038019A1 (de) | 2000-08-04 | 2002-02-14 | Bayer Ag | Substituierte Triazolopyrid(az)ine |
| US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6562989B2 (en) | 2000-08-07 | 2003-05-13 | Yale University | Catalyst for aromatic C—O, C—N, and C—C bond formation |
| TWI259180B (en) | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
| AR030357A1 (es) | 2000-08-18 | 2003-08-20 | Lundbeck & Co As H | Derivados 4 -, 5 -, 6 - y 7-indol |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| WO2003084997A1 (en) | 2001-04-10 | 2003-10-16 | Transtech Pharma, Inc. | Probes, systems and methods for drug discovery |
| CA2440842A1 (en) | 2001-04-16 | 2002-10-24 | Eisai Co., Ltd. | Novel 1h-indazole compounds |
| DK1404653T3 (da) * | 2001-06-28 | 2008-10-06 | Pfizer Prod Inc | Triamid-substituerede indoler, benzofuraner og benzothiophener som inhibitorer for mikrosomal triglycerid overförselsprotein (MTP) og/eller apolipoprotein B (ApoB) sekretion |
| JP4558314B2 (ja) | 2001-07-20 | 2010-10-06 | ベーリンガー インゲルハイム （カナダ） リミテッド | ウイルスポリメラーゼインヒビター |
| CZ2004747A3 (cs) | 2001-12-21 | 2004-11-10 | Novo Nordisk A/S | Deriváty amidů jako GK aktivátory |
| US20060004010A1 (en) | 2002-07-10 | 2006-01-05 | Hiromu Habashita | Ccr4 antagonist and medical use thereof |
| TWI244393B (en) | 2002-08-06 | 2005-12-01 | Idenix Pharmaceuticals Inc | Crystalline and amorphous forms of beta-L-2'-deoxythymidine |
| US20060083784A1 (en) | 2002-08-07 | 2006-04-20 | Smithkline Beecham Corporation | Amorphous pharmaceutical compositions |
| CA2500498C (en) | 2002-09-30 | 2012-08-21 | The Regents Of The University Of California | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof |
| JP2004131393A (ja) | 2002-10-08 | 2004-04-30 | Kowa Co | 易溶出性製剤 |
| JP4227389B2 (ja) * | 2002-10-09 | 2009-02-18 | 浜松ホトニクス株式会社 | 撮像装置及びその製造方法 |
| CA2501547A1 (en) * | 2002-10-15 | 2004-04-29 | Rigel Pharmaceuticals, Inc. | Substituted indoles and their use as hcv inhibitors |
| FR2846327B1 (fr) | 2002-10-25 | 2006-03-24 | Merck Sante Sas | Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant. |
| JP2006513159A (ja) * | 2002-11-01 | 2006-04-20 | メルク エンド カムパニー インコーポレーテッド | アンドロゲン受容体モジュレーターとしてのカルボニルアミノ−ベンズイミダゾール誘導体 |
| WO2004056744A1 (en) * | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| DE10306941A1 (de) | 2003-02-18 | 2004-08-26 | Merck Patent Gmbh | Benzofuranoxyethylamine |
| WO2004080972A1 (en) | 2003-03-12 | 2004-09-23 | Vertex Pharmaceuticals Incorporated | Pirazole modulators of atp-binding cassette transporters |
| ATE430139T1 (de) | 2003-04-03 | 2009-05-15 | Merck Patent Gmbh | Pyrrolidin-1,2-dicarbonsäure-1-(phenylamid)-2-( - (3-oxo-morpholin-4-yl)-phenylamid) derivate und verwandte verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen |
| CN104056278B (zh) | 2003-04-11 | 2017-01-18 | Ptc 治疗公司 | 1,2,4‑噁二唑苯甲酸化合物 |
| US7696244B2 (en) | 2003-05-16 | 2010-04-13 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
| EP1646615B1 (en) | 2003-06-06 | 2009-08-26 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as modulators of atp-binding cassette transporters |
| ATE554766T1 (de) | 2003-06-27 | 2012-05-15 | Jackson H M Found Military Med | Amphiphile pyridinium-verbindungen, herstellungsverfahren und ihre verwendung |
| JP4713474B2 (ja) * | 2003-08-15 | 2011-06-29 | ハー・ルンドベック・アクチエゼルスカベット | Ｎｋ３受容体アンタゴニストとしてのシクロプロピル誘導体 |
| EP1656349B1 (en) * | 2003-08-15 | 2011-10-12 | H. Lundbeck A/S | Cyclopropyl derivatives as nk3 receptor antagonists |
| CA2537841A1 (en) | 2003-09-06 | 2005-03-24 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| US20050070718A1 (en) | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
| US7598412B2 (en) | 2003-10-08 | 2009-10-06 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| WO2005037802A1 (ja) | 2003-10-16 | 2005-04-28 | Sankyo Company, Limited | ５－アリールピリミジン誘導体 |
| JPWO2005040135A1 (ja) | 2003-10-24 | 2007-03-08 | 小野薬品工業株式会社 | 抗ストレス薬およびその医薬用途 |
| NZ547220A (en) | 2003-11-14 | 2009-12-24 | Vertex Pharma | Thiazoles and oxazoles useful as modulators of ATP-binding cassette transporters |
| GB0330043D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
| ES2631362T3 (es) | 2004-01-30 | 2017-08-30 | Vertex Pharmaceuticals Incorporated | Moduladores de transportadores de casete de unión a ATP |
| WO2007056341A1 (en) | 2005-11-08 | 2007-05-18 | Vertex Pharmaceuticals Incorporated | Heterocyclic modulators of atp-binding cassette transporters |
| US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| AU2005211385B2 (en) | 2004-02-02 | 2008-12-11 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
| EP1740532A4 (en) | 2004-03-30 | 2009-06-10 | Univ California | CFTR INHIBITOR COMPOUNDS CONTAINING HYDRAZIDS AND USES THEREOF |
| US20050222271A1 (en) | 2004-03-31 | 2005-10-06 | Le Huang | Novel amorphous form of memantine hydrochloride |
| EP1766062A4 (en) | 2004-06-01 | 2008-07-09 | Tm Bioscience Corp | METHOD FOR DETECTING MUTATIONS ASSOCIATED WITH CYSTIC FIBROSIS |
| US7939558B2 (en) | 2004-06-04 | 2011-05-10 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
| US20140343098A1 (en) | 2004-06-24 | 2014-11-20 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| EP2532650A3 (en) | 2004-06-24 | 2013-11-06 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| US20060000401A1 (en) | 2004-07-01 | 2006-01-05 | Massetti Joseph A | Mooring line storage device |
| EP1771158A4 (en) | 2004-07-02 | 2008-03-12 | Advancis Pharmaceutical Corp | TABLET FOR PULSE DISTRIBUTION |
| CN1993339B (zh) | 2004-08-06 | 2013-05-22 | 大塚制药株式会社 | 芳香化合物 |
| DE102004047254A1 (de) | 2004-09-29 | 2006-04-13 | Merck Patent Gmbh | Carbonylverbindungen |
| EP2311455B1 (en) | 2004-10-13 | 2015-07-15 | PTC Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
| JP5024039B2 (ja) | 2005-02-25 | 2012-09-12 | 小野薬品工業株式会社 | インドール化合物およびその用途 |
| EP2363128B1 (en) | 2005-03-11 | 2016-02-17 | Vertex Pharmaceuticals Incorporated | Indole modulators of ATP-binding cassette transporters |
| AU2006227833A1 (en) | 2005-03-18 | 2006-09-28 | The Regents Of The University Of California | Compounds having activity in correcting mutant-CFTR processing and uses thereof |
| US7297700B2 (en) | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| EP1864978A4 (en) | 2005-03-28 | 2009-07-01 | Toyama Chemical Co Ltd | PROCESS FOR PREPARING 1- (3- (2- (1-BENZOTHIOPHEN-5-YL) ETHOXY) PROPYL) AZETIDIN-3-OL OR SALTS THEREOF |
| PL2402002T3 (pl) | 2005-04-08 | 2018-11-30 | Ptc Therapeutics, Inc. | Kompozycje zawierające kwas 1,2,4-oksadiazolobenzoesowy i ich zastosowania do leczenia chorób związanych z przedwczesnym kodonem stop |
| JP5426878B2 (ja) | 2005-05-24 | 2014-02-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｐ−結合カセットトランスポーターのモジュレーター |
| MX2008002019A (es) | 2005-08-11 | 2008-04-16 | Vertex Pharma | Moduladores del regulador de conductancia transmembrana de fibrosis quistica. |
| ES2367844T3 (es) | 2005-08-11 | 2011-11-10 | Vertex Pharmaceuticals, Inc. | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística. |
| CN101272767B (zh) | 2005-08-29 | 2012-08-29 | 赛诺菲-安万特美国有限责任公司 | 7-氯-N,N,5-三甲基-4-氧-3-苯基-3,5-二氢-4H-哒嗪并[4,5-b]吲哚-1-乙酰胺的无定形固体分散体 |
| WO2007044560A2 (en) | 2005-10-06 | 2007-04-19 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| US7401405B2 (en) * | 2005-10-11 | 2008-07-22 | Silverbrook Research Pty Ltd | Method of fabricating inkjet nozzles having associated ink priming features |
| US20120232059A1 (en) | 2005-11-08 | 2012-09-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette Transporters |
| ES2612377T3 (es) | 2005-12-21 | 2017-05-16 | Janssen Pharmaceutica N.V. | Triazolopiridazinas como moduladores de tirosina cinasas |
| WO2007075901A2 (en) | 2005-12-24 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Quinolin- 4 - one derivatives as modulators of abc transporters |
| CA2635214A1 (en) | 2005-12-27 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Compounds useful in cftr assays and methods therewith |
| EP3219705B1 (en) | 2005-12-28 | 2020-03-11 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| EP2016065B1 (en) | 2005-12-28 | 2012-09-19 | Vertex Pharmaceuticals Incorporated | 1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis |
| US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| EP2001498A4 (en) | 2006-03-20 | 2013-01-23 | Vertex Pharma | PHARMACEUTICAL COMPOSITIONS |
| US20070218012A1 (en) | 2006-03-20 | 2007-09-20 | Bittorf Kevin J | Pharmaceutical Compositions |
| ES2659364T3 (es) | 2006-04-07 | 2018-03-15 | Vertex Pharmaceuticals Incorporated | Moduladores de transportadores del casete de unión a ATP |
| US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| CN101478964B (zh) | 2006-05-12 | 2012-02-29 | 沃泰克斯药物股份有限公司 | N-[2,4-双(1,1-二甲基乙基)-5-羟苯基]-1,4-二氢-4-氧代喹啉-3-羧酰胺的组合物 |
| EP2081937B1 (en) | 2006-10-23 | 2012-09-12 | SGX Pharmaceuticals, Inc. | Triazolopyridazine protein kinase modulators |
| NZ576642A (en) | 2006-11-03 | 2011-11-25 | Vertex Pharma | Azaindole derivatives as cftr modulators |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| US20080132560A1 (en) | 2006-11-21 | 2008-06-05 | San-Laung Chow | Solid dispersion composition |
| WO2008065732A1 (fr) | 2006-11-27 | 2008-06-05 | Nippon Polyurethane Industry Co., Ltd. | Procédé de production d'un mélange à base d'isocyanate modifié contenant une liaison allophanate et une liaison isocyanurate |
| US20080260820A1 (en) | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| NZ581259A (en) | 2007-05-09 | 2012-07-27 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| ES2548292T3 (es) | 2007-05-25 | 2015-10-15 | Vertex Pharmaceuticals Incorporated | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| WO2009023509A2 (en) | 2007-08-09 | 2009-02-19 | Vertex Pharmaceuticals Incorporated | Therapeutic combinations useful in treating cftr related diseases |
| JP5389030B2 (ja) | 2007-08-24 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | （特に）嚢胞性線維症の処置に有用なイソチアゾロピリジノン |
| CN101821266B (zh) | 2007-09-14 | 2014-03-12 | 沃泰克斯药物股份有限公司 | 囊性纤维化跨膜通道调节因子的调节剂 |
| CA2699292A1 (en) | 2007-09-14 | 2009-03-26 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| SI2578571T1 (sl) | 2007-11-16 | 2016-01-29 | Vertex Pharmaceuticals Incorporated | Izokinolinski modulatorji prenašalcev z atp-vezavno kaseto |
| CN101883765B (zh) | 2007-11-22 | 2014-10-01 | 全药工业株式会社 | 杂环化合物的无定形物、含有该无定形物的固体分散体、药剂及其制备方法 |
| WO2009073757A1 (en) | 2007-12-07 | 2009-06-11 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
| US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| CA2708146A1 (en) | 2007-12-07 | 2009-06-18 | Vertex Pharmaceuticals Incorporated | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| PT2639223T (pt) | 2007-12-07 | 2017-05-08 | Vertex Pharma | Processos para produção de ácidos cicloalquilcarboxamido-piridinabenzoicos |
| JP5637859B2 (ja) | 2007-12-13 | 2014-12-10 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター |
| CN102245573B (zh) | 2008-02-28 | 2013-11-20 | 沃泰克斯药物股份有限公司 | 作为cftr调节剂的杂芳基衍生物 |
| EP2615085B1 (en) | 2008-03-31 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Pyridyl derivatives as CFTR modulators |
| CN102076339A (zh) | 2008-04-24 | 2011-05-25 | 百时美施贵宝公司 | 埃坡霉素D在治疗包括阿尔茨海默病的τ相关疾病中的用途 |
| JP5575768B2 (ja) | 2008-08-13 | 2014-08-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | 薬学的組成物およびその投与 |
| US20100256184A1 (en) | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| CN102164587A (zh) | 2008-09-29 | 2011-08-24 | 沃泰克斯药物股份有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的剂量单元 |
| US20110257223A1 (en) | 2008-10-23 | 2011-10-20 | Vertex Pharmaceuticals Incorporated | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator |
| WO2010048526A2 (en) | 2008-10-23 | 2010-04-29 | Vertex Pharmaceuticals, Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2010048564A1 (en) | 2008-10-23 | 2010-04-29 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| AU2009308241B2 (en) | 2008-10-23 | 2016-01-07 | Vertex Pharmaceuticals Incorporated | Solid forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl) phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide |
| UA104876C2 (uk) | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятори atф-зв'язувальних касетних транспортерів |
| EP2940016A1 (en) | 2008-11-06 | 2015-11-04 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| EP2382197B1 (en) | 2008-12-30 | 2016-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| NO2821400T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2009-03-20 | 2018-02-24 | ||
| EP2408749B1 (en) | 2009-03-20 | 2018-05-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2011035139A1 (en) | 2009-09-17 | 2011-03-24 | Vertex Pharmaceuticals Incorporated | Process for preparing azabicyclic compounds |
| WO2011050325A1 (en) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
| MX2012004791A (es) | 2009-10-23 | 2013-02-01 | Vertex Pharma | Formas sólidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2-(trifluo rometil)fenil)-4-oxo-5-(trifluorometil)-1,4-dihidroquinolina-3-ca rboxamida. |
| CA2778492A1 (en) | 2009-10-23 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Process for preparing modulators of cystic fibrosis transmembrane conductance regulator |
| EP3037415A1 (en) | 2010-03-19 | 2016-06-29 | Vertex Pharmaceuticals Inc. | Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| EP2826776B1 (en) | 2010-03-25 | 2020-11-25 | Vertex Pharmaceuticals Incorporated | Solid dispersion of amorphous form of (r)-1(2,2-difluorobenzo(d)(1,3)dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)-cyclopropanecarboxamide |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| ES2579965T3 (es) | 2010-04-07 | 2016-08-17 | Vertex Pharmaceuticals Incorporated | Las formas sólidas de 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) Ciclopropano carboxamida)-3-metilpiridin-2-il)benzoico |
| CN102917692A (zh) | 2010-04-07 | 2013-02-06 | 弗特克斯药品有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的药物组合物和其给药方法 |
| CA2796602A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| WO2011133956A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| WO2011133951A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| SG184987A1 (en) | 2010-04-22 | 2012-11-29 | Vertex Pharma | Process of producing cycloalkylcarboxamido-indole compounds |
| EP2386606B1 (fr) | 2010-04-30 | 2018-03-21 | Total Marketing Services | Utilisation de dérivés organogelateurs dans des compositions bitumineuses pour améliorer leur résistance aux agressions chimiques |
| WO2011146886A1 (en) | 2010-05-20 | 2011-11-24 | Vertex Pharmaceuticals Incorporated | Processes for producing modulators of cystic fibrosis transmembrane conductance regulator |
| WO2011146901A1 (en) | 2010-05-20 | 2011-11-24 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
| JP2013536231A (ja) | 2010-08-23 | 2013-09-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | （ｒ）−１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）−ｎ−（１−（２，３−ジヒドロキシプロピル）−６−フルオロ−２−（１−ヒドロキシ−２−メチルプロパン−２−イル）−１ｈ−インドール−５−イル）シクロプロパンカルボキサミドを含む医薬組成物およびその投与 |
| US20120064157A1 (en) | 2010-08-27 | 2012-03-15 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| AU2012332225A1 (en) | 2011-11-02 | 2014-05-15 | Vertex Pharmaceuticals Incorporated | Use of (N- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - ca rboxamide) for treating CFTR mediated diseases |
| RU2640420C2 (ru) | 2011-11-08 | 2018-01-09 | Вертекс Фармасьютикалз Инкорпорейтед | Модуляторы транспортеров атф-связывающей кассеты |
| US20140127901A1 (en) | 2012-11-08 | 2014-05-08 | Taiwan Semiconductor Manufacturing Company, Ltd. | Low-k damage free integration scheme for copper interconnects |
| HUE044676T2 (hu) | 2012-01-25 | 2019-11-28 | Vertex Pharma | 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav készítmények |
| US20130224293A1 (en) | 2012-02-27 | 2013-08-29 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| EP2858645A1 (en) | 2012-06-08 | 2015-04-15 | Vertex Pharmaceuticals Incorporated | Pharmaceuticl compositions for the treatment of cftr -mediated disorders |
| AR092857A1 (es) | 2012-07-16 | 2015-05-06 | Vertex Pharma | Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas |
| UA117464C2 (uk) | 2012-11-02 | 2018-08-10 | Вертекс Фармасьютікалз Інкорпорейтед | Фармацевтична композиція для лікування захворювання, опосередкованого трансмембранним регулятором провідності муковісцидозу cftr |
| US20140221424A1 (en) | 2013-01-30 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for use in the treatment of cystic fibrosis |
| WO2014210159A1 (en) | 2013-06-26 | 2014-12-31 | Proteostasis Therapeutics, Inc. | Methods of modulating cftr activity |
| AU2014349010C1 (en) | 2013-11-12 | 2020-08-06 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases |
| KR20210082557A (ko) | 2013-12-27 | 2021-07-05 | 추가이 세이야쿠 가부시키가이샤 | 토포글리플로진을 함유하는 고형 제제 및 그 제조 방법 |
| UA124567C2 (uk) | 2014-04-15 | 2021-10-13 | Вертекс Фармасьютикалз Інкорпорейтед | Фармацевтичні композиції для лікування захворювань, опосередкованих муковісцидозним регулятором трансмембранної провідності |
| NZ768373A (en) | 2014-10-06 | 2024-03-22 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| RU2749213C2 (ru) | 2014-10-07 | 2021-06-07 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе |
| PT3221692T (pt) | 2014-11-18 | 2021-09-10 | Vertex Pharma | Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência |
| MA41031A (fr) | 2014-11-26 | 2017-10-03 | Catabasis Pharmaceuticals Inc | Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie |
| WO2016086136A1 (en) | 2014-11-26 | 2016-06-02 | Catabasis Pharmaceuticals, Inc. | Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders |
| HK1249893A1 (zh) | 2015-03-31 | 2018-11-16 | Vertex Pharmaceuticals (Europe) Limited | 氘代vx-661 |
| WO2018183367A1 (en) | 2017-03-28 | 2018-10-04 | Van Goor Fredrick F | Methods of treating cystic fibrosis in patients with residual function mutations |
-
2007
- 2007-04-09 ES ES16155334.2T patent/ES2659364T3/es active Active
- 2007-04-09 EP EP13167785.8A patent/EP2674428B1/en active Active
- 2007-04-09 NZ NZ571803A patent/NZ571803A/en unknown
- 2007-04-09 SI SI200732005T patent/SI3091011T1/en unknown
- 2007-04-09 SI SI200732178T patent/SI3327016T1/sl unknown
- 2007-04-09 DK DK07755298.2T patent/DK2007756T3/en active
- 2007-04-09 NZ NZ61148507A patent/NZ611485A/en unknown
- 2007-04-09 HU HUE16155334A patent/HUE036165T2/hu unknown
- 2007-04-09 PL PL13167785T patent/PL2674428T3/pl unknown
- 2007-04-09 WO PCT/US2007/008975 patent/WO2007117715A2/en active Application Filing
- 2007-04-09 SI SI200731695T patent/SI2007756T1/sl unknown
- 2007-04-09 US US11/786,001 patent/US7776905B2/en active Active
- 2007-04-09 CN CNA2007800210737A patent/CN101460489A/zh active Pending
- 2007-04-09 CN CN2013100749078A patent/CN103254177A/zh active Pending
- 2007-04-09 CA CA2869945A patent/CA2869945C/en active Active
- 2007-04-09 EP EP17209175.3A patent/EP3327016B1/en active Active
- 2007-04-09 NZ NZ596889A patent/NZ596889A/xx unknown
- 2007-04-09 DK DK13167785.8T patent/DK2674428T3/en active
- 2007-04-09 ES ES13167785.8T patent/ES2580803T3/es active Active
- 2007-04-09 ES ES07755298.2T patent/ES2554353T3/es active Active
- 2007-04-09 JP JP2009504359A patent/JP5420395B2/ja active Active
- 2007-04-09 PL PL07755298T patent/PL2007756T3/pl unknown
- 2007-04-09 PT PT77552982T patent/PT2007756E/pt unknown
- 2007-04-09 HU HUE17209175A patent/HUE055205T2/hu unknown
- 2007-04-09 PT PT161553342T patent/PT3091011T/pt unknown
- 2007-04-09 ES ES17209175T patent/ES2882684T3/es active Active
- 2007-04-09 BR BRPI0710965A patent/BRPI0710965B8/pt active IP Right Grant
- 2007-04-09 MX MX2008012945A patent/MX2008012945A/es active IP Right Grant
- 2007-04-09 DK DK16155334.2T patent/DK3091011T3/en active
- 2007-04-09 PT PT131677858T patent/PT2674428T/pt unknown
- 2007-04-09 HU HUE13167785A patent/HUE027630T2/en unknown
- 2007-04-09 HU HUE07755298A patent/HUE026145T2/en unknown
- 2007-04-09 EP EP16155334.2A patent/EP3091011B1/en active Active
- 2007-04-09 PL PL17209175T patent/PL3327016T3/pl unknown
- 2007-04-09 PL PL16155334T patent/PL3091011T3/pl unknown
- 2007-04-09 LT LTEP16155334.2T patent/LT3091011T/lt unknown
- 2007-04-09 EP EP21156114.7A patent/EP3882245A1/en active Pending
- 2007-04-09 SI SI200731780A patent/SI2674428T1/sl unknown
- 2007-04-09 CA CA2648719A patent/CA2648719C/en active Active
- 2007-04-09 EP EP07755298.2A patent/EP2007756B1/en active Active
- 2007-04-09 RU RU2008144124/04A patent/RU2451018C2/ru active
- 2007-04-09 IN IN2423KON2014 patent/IN2014KN02423A/en unknown
- 2007-04-09 AU AU2007235260A patent/AU2007235260B2/en active Active
-
2008
- 2008-10-06 IL IL194576A patent/IL194576A/en active IP Right Grant
- 2008-10-29 ZA ZA200809290A patent/ZA200809290B/xx unknown
-
2010
- 2010-07-02 US US12/829,879 patent/US8598181B2/en active Active
-
2013
- 2013-10-21 US US14/058,839 patent/US8912199B2/en active Active
- 2013-11-20 JP JP2013240205A patent/JP5827297B2/ja active Active
-
2014
- 2014-11-04 US US14/532,791 patent/US20150119441A1/en not_active Abandoned
-
2015
- 2015-03-31 JP JP2015073706A patent/JP2015120762A/ja active Pending
- 2015-11-25 CY CY20151101060T patent/CY1116979T1/el unknown
-
2016
- 2016-05-24 US US15/162,887 patent/US9758510B2/en active Active
- 2016-07-05 CY CY20161100628T patent/CY1117731T1/el unknown
-
2017
- 2017-07-26 US US15/659,926 patent/US10239867B2/en active Active
-
2018
- 2018-03-19 CY CY20181100319T patent/CY1120045T1/el unknown
-
2019
- 2019-02-15 US US16/276,887 patent/US10975061B2/en active Active
-
2021
- 2021-02-22 US US17/181,931 patent/US11639347B2/en active Active
-
2023
- 2023-02-10 US US18/108,053 patent/US20240092766A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009533351A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| KR100704142B1 (ko) | 사람 퍼옥시좀 증식 활성화 수용체(ＰＰＡＲ)α의 효능제로서의 치환된 페닐프로피온산 유도체 | |
| RU2515968C2 (ru) | 5-членное гетероциклическое соединение и его применение для лекарственных целей | |
| JP2010528089A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| FI93208C (fi) | Dikarboksyylihappo-bis(3,5-dikarbamoyyli-2,4,6-trijodianilideja), menetelmä niiden valmistamiseksi sekä niitä sisältävät röntgenvarjoaineet | |
| JP5161569B2 (ja) | ＭＴＰおよびＡｐｏＢの新規なアザインドール阻害剤 | |
| RU2007148924A (ru) | Производные 4-или 5-аминосалицыловой кислоты | |
| JPWO2007043401A1 (ja) | 含窒素複素環化合物およびそれを含有する医薬組成物 | |
| JP2007230909A (ja) | 置換イソキサゾール誘導体 | |
| BRPI0207664B1 (pt) | Omega-aminoalkylamides of (R) -2-aryl-propionic acids as inhibitors of polymorphonuclear and mononuclear cell chemotaxis, their preparation process, and pharmaceutical composition | |
| JP2009517417A (ja) | Ｃｒｔｈ２レセプター活性を有するオキサジアゾール誘導体類 | |
| JP7575099B2 (ja) | 呼吸器疾患の処理のための新規な化合物 | |
| JP2005539081A (ja) | 芳香族肝臓ｘ受容体モジュレーター | |
| JPWO2008126901A1 (ja) | 含窒素複素環化合物およびそれを含有する医薬組成物 | |
| JP2009537595A (ja) | ヒトパピローマウイルス阻害剤としてのピペリジン誘導体 | |
| WO2009035168A1 (ja) | ４－カルバモイル－５－ヒドロキシ－イミダゾール誘導体のスルホン酸塩化合物 | |
| JP2018512424A (ja) | エステル化のための試薬及び方法 | |
| ZA200306884B (en) | N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermidiate for the compound and processes for producing the same | |
| ES2322765T3 (es) | Agonistas del receptor ep2. | |
| JP2022523738A (ja) | 標的ユビキチン化分解ｂｒｄ４タンパク質化合物、その調製方法および応用 | |
| JP2008503447A (ja) | Ｃｒｔｈ２リガンドとしての置換チアゾール酢酸 | |
| JP2007532582A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JP2012502070A (ja) | アミロイド斑結合及び造影のためのピペラジン誘導体及びそれらの使用 | |
| WO2000027792A1 (en) | Novel compounds and medicinal use thereof | |
| JP2006500409A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |